NCX-1000

DB16026InvestigationalSmall molecule

NCX-1000 is under investigation in clinical trial NCT00414869 (Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure).

Mechanism: Pharmacologically active on Caspase-3, Caspase-8, and Caspase-9
Curator reviewed
Formula / weight: C₃₈H₅₅NO₁₀ · 685.855 g/mol (avg)
Also known as: ,no-udca · no-UDCA · No-ursodeoxycholic acid
Code names: NCX-1000

Resolves to

Compound

UNIIV9G7HR5L1QCAS401519-96-8

Structure

InChIKeyWTAVOESJEWSDJC-OBOLPPCUSA-NSMILES

[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(=O)OC1=CC=C(\C=C\C(=O)OCCCCO[N+]([O-])=O)C=C1OC

Targets

P42574CASP3Q14790CASP8P55211CASP9

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with NCX-1000, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account